Yıl: 2023 Cilt: 34 Sayı: 5 Sayfa Aralığı: 552 - 559 Metin Dili: İngilizce DOI: 10.5152/tjg.2023.22297 İndeks Tarihi: 01-06-2023

Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments

Öz:
Background: Hepatitis B Virus (HBV) screening rates before starting immunosuppressive treatments are suboptimal. The aim of the study was to evaluate the efficacy of a new electronic alert system in increasing HBV screening rates. Methods: The electronic alert system, HBVision2, identifies patients at risk of HBV reactivation when a pre-determined International Classification of Diseases (ICD)-10 code is entered into the hospital’s database or immunosuppressive treatment is prescribed. The system evaluates the prior Hepatitis B Surfage Antigen (HBsAg) and anti-Hepatitis B Core Immunglobulin G (HBc IgG) results and sends an alert code to the clinician for screening if serology is not completely available or consult a specialist in case of positive serology. The HBV screening and consultation rates of patients before (control group) and after HBVision2 were retrospectively compared. The clini- cal course of unscreened and/or unconsulted patients was determined, and the clinical efficacy of HBVision2 in preventing HBVr was predicted. Results: Control group included 815 patients (52.6% male, mean age: 60 ± 12, 82.5% with oncologic malignancy) and study group included 504 patients (56% male, mean age: 60 ± 13, 91.4% with oncologic malignancy). Groups were similar with respect to gender, mean age, and HBVr risk profile of the immunosuppressive treatment protocols. Overall, both HBsAg (from 55.1% to 93.1%) and anti- HBc IgG screening rates significantly increased (from 4.3% to 79.4%) after the electronic alert system (P < .001, for both). Consultation rates of anti-HBc IgG-positive patients significantly increased from 40% to 72.7% (P = .012). HBVr developed in 2 patients (2.6%) who were not screened and/or consulted after the alert system. Alert program prevented the development of HBVr in 10 patients (1.9%) of the study group and decreased the development of HBVr by 80%. Conclusion: Electronic alert system significantly improved HBsAg and anti-HBc IgG screening rates before starting immunosuppressive treatment and prevented the development of HBVr to a great extent. However, screening rates are still below optimal and need to be improved.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009; 49(5):S156-S165. [CrossRef]
  • 2. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients under- going chemotherapy. Gastroenterology. 2003;125(6):1742-1749. [CrossRef]
  • 3. Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31(22):2765-2772. [CrossRef]
  • 4. Toka B, Koksal AS, Eminler AT, Tozlu M, Uslan MI, Parlak E. Comparison of tenofovir disoproxil fumarate and entecavir in the prophylaxis of HBV reactivation. Dig Dis Sci. 2021;66(7):2417-2426. [CrossRef]
  • 5. European Association For The Study Of The Liver. EASL clinical practice guidelines. Management of chronic hepatitis B virus infec- tion. J Hepatol. 2012;57(1):167-185. [CrossRef]
  • 6. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6(3):531-561. [CrossRef]
  • 7. Weinbaum CM, Mast EE, Ward JW. Recommendations for identi- fication and public health management of persons with chronic hepatitis B virus infection. Hepatology. 2009;49(5)(suppl):S35-S44. [CrossRef]
  • 8. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Clin Liver Dis (Hoboken). 2018;12(1):33-34. [CrossRef]
  • 9. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-244.e3. [CrossRef]
  • 10. Hwang JP, Artz AS, Somerfield MR. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Oncol Pract. 2015; 11(4):e487-e489. [CrossRef]
  • 11. Kwak YE, Stein SM, Lim JK. Practice patterns in hepatitis B virus screening before cancer chemotherapy in a major US hospital net- work. Dig Dis Sci. 2018;63(1):61-71. [CrossRef]
  • 12. Lok AS, Ward JW, Perrillo RP, McMahon BJ, Liang TJ. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med. 2012;156(10):743-745. [CrossRef]
  • 13. Köksal AS, Toka B, Eminler AT, et al. The efficacy of a computer alert programme for increasing HBV screening rates before starting immunosuppressive therapy. Acta Gastroenterol Belg. 2019;82(2): 279-284.
  • 14. Hwang JP, Barbo AG, Perrillo RP. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. J Viral Hepat. 2015;22(3):346-352. [CrossRef]
  • 15. Toka B, Koksal AS, İskender G, et al. HBV flare associated with immunosuppressive treatments: it is still dangerous in the third-generation antivirals era. Antivir Ther. 2020;25(3):121-129. [CrossRef]
  • 16. Wi CI, Loo NM, Larson JJ, et al. Low level of hepatitis B virus screening among patients receiving chemotherapy. Clin Gastroen- terol Hepatol. 2015;13(5):970-5; quiz e51. [CrossRef]
  • 17. Sampedro B, Hernández-López C, Ferrandiz JR, et al. Computer- ized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project. Hepatology. 2014;60(1):106-113. [CrossRef]
  • 18. Sanagawa A, Kuroda J, Shiota A, et al. Outcomes of the imple- mentation of the computer-assisted HBView system for the preven- tion of hepatitis B virus reactivation in chemotherapy patients: a retrospective analysis. J Pharm Health Care Sci. 2015;1:29. [CrossRef]
  • 19. Sun WC, Hsu PI, Yu HC, et al. The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system. PLOS ONE. 2015;10(2):1-16. [CrossRef]
  • 20. Riveiro-Barciela M, Gubern P, Roade L, et al. An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders [sci rep]. Sci Rep. 2020;10(1):3038. [CrossRef]
  • 21. Ikeda M, Yamamoto H, Kaneko M, et al. Screening rate for hepa- titis B virus infection in patients undergoing chemotherapy in Japan. Int J Clin Oncol. 2016;21(6):1162-1166. [CrossRef]
  • 22. Hwang JP, Fisch MJ, Zhang H, et al. Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract. 2012;8(4): e32-e39. [CrossRef]
APA Köksal A, toka b, Sadecolak M, ACAR S, Eminler A, tozlu m, KARABAY O (2023). Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments. , 552 - 559. 10.5152/tjg.2023.22297
Chicago Köksal Aydın,toka bilal,Sadecolak Mustafa,ACAR SENCAN,Eminler Ahmet Tarik,tozlu mukaddes,KARABAY OĞUZ Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments. (2023): 552 - 559. 10.5152/tjg.2023.22297
MLA Köksal Aydın,toka bilal,Sadecolak Mustafa,ACAR SENCAN,Eminler Ahmet Tarik,tozlu mukaddes,KARABAY OĞUZ Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments. , 2023, ss.552 - 559. 10.5152/tjg.2023.22297
AMA Köksal A,toka b,Sadecolak M,ACAR S,Eminler A,tozlu m,KARABAY O Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments. . 2023; 552 - 559. 10.5152/tjg.2023.22297
Vancouver Köksal A,toka b,Sadecolak M,ACAR S,Eminler A,tozlu m,KARABAY O Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments. . 2023; 552 - 559. 10.5152/tjg.2023.22297
IEEE Köksal A,toka b,Sadecolak M,ACAR S,Eminler A,tozlu m,KARABAY O "Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments." , ss.552 - 559, 2023. 10.5152/tjg.2023.22297
ISNAD Köksal, Aydın vd. "Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments". (2023), 552-559. https://doi.org/10.5152/tjg.2023.22297
APA Köksal A, toka b, Sadecolak M, ACAR S, Eminler A, tozlu m, KARABAY O (2023). Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments. Turkish Journal of Gastroenterology, 34(5), 552 - 559. 10.5152/tjg.2023.22297
Chicago Köksal Aydın,toka bilal,Sadecolak Mustafa,ACAR SENCAN,Eminler Ahmet Tarik,tozlu mukaddes,KARABAY OĞUZ Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments. Turkish Journal of Gastroenterology 34, no.5 (2023): 552 - 559. 10.5152/tjg.2023.22297
MLA Köksal Aydın,toka bilal,Sadecolak Mustafa,ACAR SENCAN,Eminler Ahmet Tarik,tozlu mukaddes,KARABAY OĞUZ Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments. Turkish Journal of Gastroenterology, vol.34, no.5, 2023, ss.552 - 559. 10.5152/tjg.2023.22297
AMA Köksal A,toka b,Sadecolak M,ACAR S,Eminler A,tozlu m,KARABAY O Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments. Turkish Journal of Gastroenterology. 2023; 34(5): 552 - 559. 10.5152/tjg.2023.22297
Vancouver Köksal A,toka b,Sadecolak M,ACAR S,Eminler A,tozlu m,KARABAY O Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments. Turkish Journal of Gastroenterology. 2023; 34(5): 552 - 559. 10.5152/tjg.2023.22297
IEEE Köksal A,toka b,Sadecolak M,ACAR S,Eminler A,tozlu m,KARABAY O "Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments." Turkish Journal of Gastroenterology, 34, ss.552 - 559, 2023. 10.5152/tjg.2023.22297
ISNAD Köksal, Aydın vd. "Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments". Turkish Journal of Gastroenterology 34/5 (2023), 552-559. https://doi.org/10.5152/tjg.2023.22297